- $1.03tn
- $1.07tn
- $65.18bn
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
Brief: Eli Lilly Declares Q3 2026 Dividend Of $1.73 Per Share
Germany's Merz says current EU budget proposals unaffordable
U.S. RESEARCH ROUNDUP- Albemarle, Carmax, Kroger
Brief: Charles River Laboratories International Announces Collaboration With Lilly Tunelab
Analysis: Big pharma taps UK playbook to pressure European capitals on drug prices
US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugs
Brief: 4E Therapeutics Acquired By Lilly To Advance Non-Opioid Approach To Chronic Pain
Novo Nordisk to seek approval soon to sell Wegovy pill in China (updated)
German government to abandon variable drug discounting plans, source tells Reuters (updated)
Factbox: Global drugmakers invest billions to boost US presence
Brief: Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll
Drugmakers will not be exempt from cost cuts, says German health minister